MX389474B - Dimetilfumarato y regimenes de vacunacion. - Google Patents
Dimetilfumarato y regimenes de vacunacion.Info
- Publication number
- MX389474B MX389474B MX2016012052A MX2016012052A MX389474B MX 389474 B MX389474 B MX 389474B MX 2016012052 A MX2016012052 A MX 2016012052A MX 2016012052 A MX2016012052 A MX 2016012052A MX 389474 B MX389474 B MX 389474B
- Authority
- MX
- Mexico
- Prior art keywords
- dimethyl fumarate
- vaccination regimen
- administering
- subject
- dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se provee un método de tratamiento o prevención de una enfermedad o trastorno (por ejemplo, esclerosis múltiple) en un sujeto en necesidad del mismo, que comprende: (a) administrarle al sujeto una primera dosis de una composición farmacéutica que comprende un agente de fumarato (por ejemplo, fumarato de dimetilo) durante un primer periodo de dosificación; (b) administrarle una vacuna; y (c) administrarle al sujeto una segunda dosis de la composición farmacéutica durante un segundo periodo de dosificación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461953259P | 2014-03-14 | 2014-03-14 | |
| PCT/US2015/020470 WO2015138917A1 (en) | 2014-03-14 | 2015-03-13 | Dimethyl fumarate and vaccination regimens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016012052A MX2016012052A (es) | 2017-04-27 |
| MX389474B true MX389474B (es) | 2025-03-20 |
Family
ID=52737422
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016012052A MX389474B (es) | 2014-03-14 | 2015-03-13 | Dimetilfumarato y regimenes de vacunacion. |
| MX2022000746A MX2022000746A (es) | 2014-03-14 | 2016-09-14 | Dimetilfumarato y regimenes de vacunacion. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022000746A MX2022000746A (es) | 2014-03-14 | 2016-09-14 | Dimetilfumarato y regimenes de vacunacion. |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US10391160B2 (es) |
| EP (2) | EP3116536A1 (es) |
| CA (1) | CA2942690A1 (es) |
| MA (2) | MA51730A (es) |
| MX (2) | MX389474B (es) |
| WO (1) | WO2015138917A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2942690A1 (en) | 2014-03-14 | 2015-09-17 | Biogen Ma Inc. | Dimethyl fumarate and vaccination regimens |
| MA40985A (fr) | 2014-11-17 | 2017-09-26 | Biogen Ma Inc | Méthodes de traitement de la sclérose en plaques |
| EP3250198A1 (en) * | 2014-12-04 | 2017-12-06 | Biogen MA Inc. | Multiple sclerosis treatment regimen using dimethyl fumarate |
| CN117320710A (zh) * | 2020-05-06 | 2023-12-29 | 易姆赛斯股份公司 | 用于富马酸酯相关疾病的组合治疗 |
| CA3182369A1 (en) * | 2020-05-06 | 2021-07-22 | Imcyse Sa | Combination treatment for fumarate-related diseases |
| US20230233500A1 (en) * | 2020-06-11 | 2023-07-27 | University Of Massachusetts | Gasdermin D (GSDMD) Succination for the Treatment of Inflammatory Disease |
| AU2022246073A1 (en) * | 2021-03-25 | 2023-10-05 | The Regents Of The University Of California | Compositions and methods for inhibiting and treating viral infections |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| EP1799196B1 (en) | 2004-10-08 | 2016-06-22 | Forward Pharma A/S | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
| CN114146079A (zh) | 2012-02-07 | 2022-03-08 | 比奥根玛公司 | 含有富马酸二甲酯的药物组合物 |
| US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
| AU2015222880B2 (en) | 2014-02-28 | 2016-11-24 | Banner Life Sciences Llc | Controlled release enteric soft capsules of fumarate esters |
| US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
| US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| CA2942690A1 (en) | 2014-03-14 | 2015-09-17 | Biogen Ma Inc. | Dimethyl fumarate and vaccination regimens |
| CA2962916C (en) | 2014-10-08 | 2021-06-15 | Banner Life Sciences Llc | Controlled release enteric soft capsules of fumarate esters |
| MA40985A (fr) | 2014-11-17 | 2017-09-26 | Biogen Ma Inc | Méthodes de traitement de la sclérose en plaques |
| WO2017040272A1 (en) | 2015-08-31 | 2017-03-09 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| WO2017151184A1 (en) | 2016-02-29 | 2017-09-08 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| US10523918B2 (en) | 2017-03-24 | 2019-12-31 | Samsung Electronics Co., Ltd. | System and method for depth map |
-
2015
- 2015-03-13 CA CA2942690A patent/CA2942690A1/en active Pending
- 2015-03-13 EP EP15712240.9A patent/EP3116536A1/en not_active Ceased
- 2015-03-13 MA MA051730A patent/MA51730A/fr unknown
- 2015-03-13 WO PCT/US2015/020470 patent/WO2015138917A1/en not_active Ceased
- 2015-03-13 MA MA039743A patent/MA39743A/fr unknown
- 2015-03-13 MX MX2016012052A patent/MX389474B/es unknown
- 2015-03-13 US US15/125,612 patent/US10391160B2/en active Active
- 2015-03-13 EP EP19199534.9A patent/EP3650042A1/en not_active Withdrawn
-
2016
- 2016-09-14 MX MX2022000746A patent/MX2022000746A/es unknown
-
2019
- 2019-04-23 US US16/391,583 patent/US10555993B2/en not_active Expired - Fee Related
- 2019-12-30 US US16/729,710 patent/US10994003B2/en not_active Expired - Fee Related
-
2021
- 2021-04-12 US US17/228,004 patent/US20210228701A1/en not_active Abandoned
- 2021-11-17 US US17/528,844 patent/US20220072117A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3116536A1 (en) | 2017-01-18 |
| MA39743A (fr) | 2017-01-18 |
| EP3650042A1 (en) | 2020-05-13 |
| MX2016012052A (es) | 2017-04-27 |
| US20170000873A1 (en) | 2017-01-05 |
| US10555993B2 (en) | 2020-02-11 |
| US20220072117A1 (en) | 2022-03-10 |
| US10391160B2 (en) | 2019-08-27 |
| MX2022000746A (es) | 2022-02-14 |
| US20190247485A1 (en) | 2019-08-15 |
| US20200360501A1 (en) | 2020-11-19 |
| WO2015138917A1 (en) | 2015-09-17 |
| US10994003B2 (en) | 2021-05-04 |
| CA2942690A1 (en) | 2015-09-17 |
| US20210228701A1 (en) | 2021-07-29 |
| MA51730A (fr) | 2020-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022000746A (es) | Dimetilfumarato y regimenes de vacunacion. | |
| EA201891186A1 (ru) | Антитела, нейтрализующие вирус иммунодефицита человека | |
| EA201691481A1 (ru) | ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ | |
| BR112018069789A2 (pt) | medicamento obtido pela combinação do agonista de fxr e arb | |
| PH12017501370A1 (en) | Bivalent swine influenza virus vaccine | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| NZ731659A (en) | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus | |
| CY1121566T1 (el) | Νευροπροστατευτικο και ενδειξη αυτου | |
| MX381617B (es) | Conjugados de peptido-curcumina y formulaciones de los mismos. | |
| BR112018015367A2 (pt) | carreadores oromucosais de nanofibra para tratamento terapêutico | |
| CY1119532T1 (el) | (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
| EA201691796A1 (ru) | П-замещенные асимметричные мочевины и их применение в медицине | |
| EA201691860A1 (ru) | Пептидный медикамент в виде сухого порошка | |
| MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. | |
| CY1119522T1 (el) | (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
| MX389844B (es) | Regimen de dosificacion para interferon pegilado. | |
| EA201792314A1 (ru) | Фармацевтическая комбинация эверолимуса и дактолисиба | |
| MD4763B1 (ro) | Compoziţie farmaceutică | |
| HK1232465A1 (en) | Dimethyl fumarate and vaccination regimens | |
| IL249483A0 (en) | Preparation methods for a novel generation of biological safe klh products used for cancer treatment, for the development of conjugated therapeutic vaccines and as challenging agents | |
| EA201892675A1 (ru) | Фармацевтическая композиция, содержащая этеплирсен | |
| IN2014DE00822A (es) |